Alcon Research is the lead sponsor of 11 current clinical trials in our USA, India and UK registers. 5 are recruiting patients now. The most common phase is Observational. The drugs named most often in its trials are Apraclonidine Ophthalmic , Unit Preservative Free and Aflibercept. The most-studied condition is Cataract.
| Study | Phase | Status | Start | Registers |
|---|---|---|---|---|
|
Capella Scientia Development Study
NCT06987474 · ClinicalTrials.gov ↗ · Cataract
|
Observational | Recruiting | 2025-07 | India |
|
Surgical Procedure Efficiency Evaluation stuDy
NCT07228091 · ClinicalTrials.gov ↗ · Cataract, Vitreous Hemorrhage, Retinal Detachment
|
Observational | Recruiting | 2026-02 | UK |
|
Hydrus® Microstent New Enrollment Post-Approval Study
NCT04553523 · Primary Open Angle Glaucoma
|
Not applicable | Recruiting | 2020-08 | USA |
|
Clareon TruPlus Study
NCT07502456 · ClinicalTrials.gov ↗ · Aphakia, Astigmatism
|
Not applicable | Recruiting | 2026-05 | USA |
|
Agreement of Two OCT Biometers: A Pilot Study
NCT07782619 · ClinicalTrials.gov ↗ · Anterior Segment of Eye, Axial Length, Biometrics Measurement
|
Observational | Recruiting | 2026-08 | USA |
|
Clinical Evaluation of a Novel Trifocal IOL
NCT07587138 · ClinicalTrials.gov ↗ · Aphakia, Cataract
|
Not applicable | Not yet open | 2026-10 | India |
|
Efficacy and Safety of FID 123472 Ophthalmic Solution for Ocular Redness in Adults
NCT07531043 · ClinicalTrials.gov ↗ · Ocular Hyperemia
|
Phase 3 | Not yet open | 2026-10 | USA |
|
UNITY DX Cornea Study
NCT07768735 · ClinicalTrials.gov ↗ · Tomography
|
Observational | Not yet open | 2026-09 | USA |
|
An Investigation of FID 123472 Ophthalmic Solution to Vehicle for the Reduction of Ocular Redness in Adults
NCT07578363 · ClinicalTrials.gov ↗ · Ocular Hyperemia
|
Phase 3 | Not yet open | 2026-09 | USA |
|
Post Market Clinical Evaluation of Clareon PanOptix Pro and Clareon PanOptix Pro Toric IOLs
NCT07161635 · ClinicalTrials.gov ↗ · Aphakia, Presbyopia
|
Not applicable | Active, closed | 2025-10 | USA |
|
Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)
NCT05769153 · ClinicalTrials.gov ↗ · Neovascular Age-related Macular Degeneration (nAMD)
Drug: Aflibercept |
Phase 1/2 | Active, closed | 2023-12 | USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 8 | 3 |
| Clinical trials in India | 2 | 1 |
| Clinical trials in UK | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
Sponsors with the most current trials registered for this condition.
Alcon Research is the lead sponsor of 11 current trials on ClinicalTrials.gov in our USA, India and UK registers, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 5 of its 11 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Its current trials name 2 drugs and biologicals as interventions. The most frequent are Apraclonidine Ophthalmic , Unit Preservative Free (2) and Aflibercept (1). The number in brackets is how many of its trials name each drug.
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.